---
schema_version: "secwatch.filing_event.v1"
accession: "0000200406-25-000110"
form_type: "8-K"
ticker: "JNJ"
cik: "0000200406"
company_name: "JOHNSON & JOHNSON"
filed_at: "2025-04-15T23:59:59+00:00"
generated_at: "2026-05-23T15:05:21.885640+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# JNJ Q1 adj EPS $2.77 (+2.2%), revenue $21.9B; dividend +4.8% to $1.30

## Summary
- GAAP net earnings $11.0B ($4.54 diluted EPS) vs $3.3B ($1.34), boosted by $7.3B other income.
- Adjusted net earnings $6.71B ($2.77 diluted EPS) vs $6.58B ($2.71), up 1.9% operationally.
- Worldwide sales $21.89B, up 2.4% reported, 4.2% operational; US +5.9%, International -1.8%.
- Innovative Medicine $13.87B (+2.3% reported, +4.2% op); MedTech $8.02B (+2.5% reported, +4.1% op).
- Dividend raised 4.8% to $1.30/quarter, payable June 10, 2025; record May 27, 2025; 63rd annual increase.

## SEC filing metadata
- accession: 0000200406-25-000110
- form_type: 8-K
- ticker: JNJ
- cik: 0000200406
- company_name: JOHNSON & JOHNSON
- filed_at: 2025-04-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/200406/000020040625000110/0000200406-25-000110-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/200406/000020040625000110/jnj-20250415.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000200406-25-000110
- JSON: https://secwatch.observer/filing/0000200406-25-000110.json
- Plain text: https://secwatch.observer/filing/0000200406-25-000110.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.